(Albany, US), November 5, 2026 – DelveInsight’s ‘Dravet Syndrome Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of Dravet syndrome, historical and forecasted epidemiology, as well as the Dravet syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Explore the intricate details of the Dravet Syndrome Market Report @ Dravet Syndrome Treatment Market Size
Key Takeaways from the Dravet Syndrome Market Report
In April 2026, Jazz Pharmaceuticals presented research on EPIDIOLEX (cannabidiol) Oral Solution in Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting.
In March 2026, Stoke Therapeutics and Biogen reported in The New England Journal of Medicine that zorevunersen showed early evidence of potential disease modification in Dravet syndrome.
In March 2026, Encoded Therapeutics announced the successful completion of its Initial Comprehensive Multidisciplinary RMAT meeting with the US FDA, with alignment on the pivotal study design supporting the planned BLA submission for ETX101.
In January 2026, Encoded Therapeutics announced that the US FDA had granted Breakthrough Therapy Designation to ETX101 for SCN1A+ Dravet syndrome.
According to DelveInsight’s analysis, the Dravet syndrome market is expected to expand at a healthy growth rate during the forecast period (2026–2036), owing to the launch of new therapies and the rise in the number of cases.
The total diagnosed prevalent cases of Dravet syndrome in the 7MM comprised ~25,600 cases in 2025.
In the 7MM, the US accounted for the highest share (~50%) of diagnosed prevalent cases of Dravet syndrome in 2025, and the US Dravet syndrome market is expected to lead in revenue.
Approximately 85% of patients with Dravet syndrome have a mutation or deletion in the SCN1A gene, which encodes a voltage-gated sodium channel protein.
Mortality affects up to 20% of children and adolescents with Dravet syndrome before adulthood, primarily due to sudden unexpected death in epilepsy, prolonged seizures, severe infections, or seizure-related accidents.
Dravet syndrome requires disease-modifying SCN1A-targeted therapies beyond symptomatic seizure control, along with comprehensive management of neurodevelopmental comorbidities and safer, lower-burden treatment options.
The leading Dravet Syndrome Companies include Stoke Therapeutics, Biogen, Longboard Pharmaceuticals, Harmony Biosciences, Encoded Therapeutics, Jazz Pharmaceuticals, UCB, Zogenix, Biocodex, and others.
Promising Dravet Syndrome Therapies include Zorevunersen (STK-001), Bexicaserin (LP352), Clemizole Hydrochloride (EPX-100), ETX101, and others.
Get a Free sample for the Dravet Syndrome Market Forecast, Size & Share Analysis Report @ Dravet Syndrome Therapeutics Market
Dravet Syndrome Overview
Dravet syndrome, previously referred to as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare, lifelong form of childhood epilepsy that is typically resistant to treatment. It is classified as a developmental and epileptic encephalopathy, in which persistent, difficult-to-control seizures contribute to significant developmental delays and cognitive impairment. The condition is primarily caused by mutations in the SCN1A gene, leading to dysfunction in neuronal sodium channels, and is characterized by prolonged, treatment-resistant seizures along with developmental delay, cognitive impairment, and behavioral issues. Seizures typically begin between 2 and 15 months of age, and early episodes are often fever-triggered and prolonged. Diagnosis is primarily based on clinical presentation, with genetic testing for SCN1A mutations key to confirmation, although not all patients test positive. Due to its complexity, Dravet syndrome requires lifelong, multidisciplinary management.
Dravet Syndrome Epidemiology Segmentation in the 7MM
Total Dravet Syndrome Diagnosed Prevalent Cases
Dravet Syndrome Mutation-specific Diagnosed Prevalent Cases
Dravet Syndrome Age-specific Diagnosed Prevalent Cases
Dravet Syndrome Gender-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Dravet Syndrome Epidemiology trends @ Dravet Syndrome Prevalence
Dravet Syndrome Epidemiology Key Findings
The prevalence of Dravet syndrome is estimated to range from 1 in 20,000 to 1 in 40,000 individuals.
Dravet syndrome shows a higher prevalence in males than in females, with a reported male-to-female ratio of approximately 2:1.
About 3–8% of infants with seizures in the first year may be diagnosed with Dravet syndrome.
Dravet syndrome is associated with mutations in the sodium channel alpha 1 subunit gene SCN1A in about 80–90% of cases.
In Spain, pediatric patients exhibit an average rate of 1.1 cases per million inhabitants, while adults show a significantly lower rate of 0.5 cases per million, underscoring the need for targeted diagnostic and treatment strategies across age groups, and shaping the Spain Dravet syndrome market.
Approved Therapies for Dravet Syndrome
Currently, EPIDIOLEX (Jazz Pharmaceuticals), DIACOMIT (Biocodex), and FINTEPLA (UCB/Zogenix), among others, are approved medications offering treatment options for patients with Dravet syndrome.
EPIDIOLEX (cannabidiol), known as EPIDYOLEX in the European Union and the United Kingdom, is a prescription, plant-derived cannabis-based oral solution. In the United States, it is indicated for the treatment of seizures associated with Dravet syndrome in patients 1 year of age and older. In the EU and UK, it is indicated as adjunctive therapy with clobazam for patients 2 years of age and older, which influences the UK Dravet syndrome market.
FINTEPLA (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. Due to risks of valvular heart disease and pulmonary arterial hypertension, it is available only through a restricted distribution program under REMS. It is also approved in the European Union and Japan.
Dravet Syndrome Pipeline Analysis
Zorevunersen (STK-001): Stoke Therapeutics and Biogen
Zorevunersen (STK-001) is an investigational antisense oligonucleotide designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene, thereby reducing both seizures and significant non-seizure comorbidities. The FDA has granted it a rare pediatric disease designation and Breakthrough Therapy Designation. As per the January 2026 JP Morgan presentation, the Phase III EMPEROR study is on track, with enrollment of 150 patients expected by Q2 2026 and data readout planned for mid-2027 to support a rolling NDA submission in H1 2027.
ETX101: Encoded Therapeutics
ETX101 is a potential one-time, disease-modifying, cell-selective gene regulation therapy for SCN1A+ Dravet syndrome, designed to address the underlying cause of the disease and its seizure, cognitive, behavioral, developmental, and motor manifestations. The US FDA has granted it Breakthrough Therapy Designation, and the company has aligned with the FDA on the pivotal study design supporting its planned BLA submission.
Discover more about therapies set to grab Major Dravet Syndrome Market Share @ Dravet Syndrome Market Drivers and Barriers
Dravet Syndrome Market Outlook
The Dravet syndrome market is progressively expanding, driven by high unmet medical needs and continuous therapeutic advancements. Current treatment is largely symptomatic, with clobazam and valproic acid widely used as first-line therapies, stiripentol and the ketogenic diet as second-line options, and levetiracetam and Vagus Nerve Stimulation supporting refractory patients. Despite these options, most patients remain inadequately controlled. Steady growth in the Germany Dravet syndrome market and the France Dravet syndrome market, alongside Japan, reflects increasing diagnosis rates, broader pediatric access, and rising adoption of novel mechanisms, while pharmaceutical companies invest in gene-targeted and disease-modifying approaches expected to reshape the future landscape. For stakeholders tracking the India Dravet syndrome market, the China Dravet syndrome market, the GCC Dravet syndrome market, and the South America Dravet syndrome market, these 7MM insights serve as a useful reference point for the global therapeutic direction.
Dravet Syndrome Market Drivers
Rising Dravet syndrome prevalence, particularly among children aged ≤16 years, driven by improved diagnosis, greater awareness, and advancements in genetic testing
Rising opportunities in targeted therapies, including gene therapies, antisense oligonucleotides, and novel neuromodulators
Shift toward disease-modifying treatments addressing underlying SCN1A dysfunction
Introduction of newer targeted drugs and increased pharmaceutical investment in pipeline innovation
Growing disease awareness and improved diagnostic approaches
Dravet Syndrome Market Barriers
Lack of curative or disease-modifying therapies targeting SCN1A
Refractory seizures, with many patients poorly controlled despite available treatments
High burden of cognitive and behavioral comorbidities
Heterogeneous treatment response, safety concerns, and high treatment burden
Contraindicated sodium channel–blocking drugs limiting therapeutic choices
Limited access to specialized genetic testing and low clinical awareness among healthcare providers
Dravet Syndrome Treatment Landscape
Dravet syndrome is managed with anti-seizure combination therapy, mainly fenfluramine, cannabidiol, stiripentol, valproate, and clobazam, with avoidance of sodium-channel blockers, which can worsen seizures. Rescue therapies, such as benzodiazepines, are used for prolonged seizures or status epilepticus. Management also includes trigger control, non-pharmacological approaches such as the ketogenic diet in some cases, and multidisciplinary long-term supportive care addressing developmental, behavioral, and cognitive comorbidities.
To know more about Dravet Syndrome Companies working in the treatment market, visit @ Dravet Syndrome Market Access and Reimbursement
Scope of the Dravet Syndrome Market Report
Coverage- 7MM
Study Period- 2022–2036
Forecast Period- 2026–2036
Dravet Syndrome Companies- Stoke Therapeutics, Biogen, Longboard Pharmaceuticals, Harmony Biosciences, Encoded Therapeutics, Jazz Pharmaceuticals, UCB, Zogenix, Biocodex, and others.
Dravet Syndrome Therapies- Cannabidiol (EPIDIOLEX/EPIDYOLEX), Fenfluramine (FINTEPLA), Stiripentol (DIACOMIT), Zorevunersen (STK-001), Bexicaserin (LP352), Clemizole Hydrochloride (EPX-100), ETX101, and others.
Dravet Syndrome Market Dynamics: Dravet syndrome market drivers and market barriers
Dravet Syndrome Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis
Dravet Syndrome Unmet Needs, KOL Views, Reimbursement
Table of Contents
Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
Dravet Syndrome Market Overview at a Glance
Disease Background and Overview of Dravet Syndrome
Treatment Guidelines for Dravet Syndrome
Epidemiology and Patient Population of Dravet Syndrome
Patient Journey of Dravet Syndrome
Marketed Therapies
Emerging Therapies
Dravet Syndrome: 7MM Analysis
Unmet Needs of Dravet Syndrome
SWOT Analysis of Dravet Syndrome
KOL Views of Dravet Syndrome
Market Access and Reimbursement of Dravet Syndrome
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/dravet-syndrome-market
